Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2009 1
2012 2
2013 1
2014 4
2015 6
2016 5
2017 2
2018 6
2019 4
2020 4
2021 5
2022 1
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for shawn labelled
Search for Shawn Labelle instead (2 results)
Improving cell-based therapies by nanomodification.
Chen W, Fu L, Chen X. Chen W, et al. J Control Release. 2015 Dec 10;219:560-575. doi: 10.1016/j.jconrel.2015.09.054. Epub 2015 Sep 28. J Control Release. 2015. PMID: 26423238 Free PMC article. Review.
Their potential applications are also discussed, including cell protection, cell labeling, targeted delivery and in situ regulation. It is believed that these novel cell-material complexes can have great potentials for biomedical applications....
Their potential applications are also discussed, including cell protection, cell labeling, targeted delivery and in situ regulation. …
Warning Labels and High-Powered Magnet Exposures.
Middelberg LK, Leonard JC, Shi J, Aranda A, Brown JC, Cochran CL, Eastep K, Haasz M, Hoffmann JA, Koral A, Lamoshi A, Levitte S, Lo YHJ, Montminy T, Myer S, Novotny NM, Parrado RH, Ruan W, Stewart AM, Talathi S, Tavarez MM, Townsend P, Zaytsev J, Rudolph B. Middelberg LK, et al. Pediatrics. 2022 Nov 1;150(5):e2022056325. doi: 10.1542/peds.2022-056325. Pediatrics. 2022. PMID: 36189482
Consenting participants responded to a standardized questionnaire regarding the presence and utility of warning labels, magnet product manufacturer, and attitudes around risk. RESULTS: Of 596 patients in the IMPACT study, 173 parents and 1 adult patient were reached …
Consenting participants responded to a standardized questionnaire regarding the presence and utility of warning labels, magnet pro …
Looking Back at 2018.
Kennedy MS. Kennedy MS. Am J Nurs. 2019 Jan;119(1):7. doi: 10.1097/01.NAJ.0000552587.92600.a4. Am J Nurs. 2019. PMID: 30589681
A review of a year some labeled 'toxic.'...
A review of a year some labeled 'toxic.'...
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
Flanagan S, Walker H, Ong V, Sandison T. Flanagan S, et al. Microbiol Spectr. 2023 Jun 15;11(3):e0133923. doi: 10.1128/spectrum.01339-23. Epub 2023 May 8. Microbiol Spectr. 2023. PMID: 37154682 Free PMC article.
While in vitro data indicated that rezafungin exposure was unlikely to be affected by commonly prescribed medicines, interactions resulting in the altered systemic exposure of some drugs coadministered with rezafungin could not be excluded. Two phase 1 open label crossover …
While in vitro data indicated that rezafungin exposure was unlikely to be affected by commonly prescribed medicines, interactions resulting …
Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product.
Cantin G, Liu Q, Shah B, Kuhns S, Wikström M, Cao S, Liu J. Cantin G, et al. Drugs R D. 2023 Dec;23(4):421-438. doi: 10.1007/s40268-023-00441-7. Epub 2023 Oct 13. Drugs R D. 2023. PMID: 37831372 Free PMC article.
BACKGROUND AND OBJECTIVE: ABP 654 is a proposed biosimilar to ustekinumab reference product (RP), a human immunoglobulin isotype class G subclass 1 kappa monoclonal antibody that acts as an antagonist of interleukin (IL)-23 and IL-12. ...METHODS: The analytical testing pla …
BACKGROUND AND OBJECTIVE: ABP 654 is a proposed biosimilar to ustekinumab reference product (RP), a human immunoglobulin isotype clas …
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Nooka AK, et al. Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25. Cancer. 2023. PMID: 37622738 Free PMC article.
METHODS: DREAMM-2 (NCT03525678) was a phase 2, two-arm, open-label trial in patients with heavily pretreated RRMM who had three or more prior therapies, were refractory to an immunomodulatory agent and a proteasome inhibitor, and refractory or intolerant to an anti-CD38 mo …
METHODS: DREAMM-2 (NCT03525678) was a phase 2, two-arm, open-label trial in patients with heavily pretreated RRMM who had three or mo …
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.
Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH. Findling RL, et al. CNS Drugs. 2021 Jun;35(6):643-653. doi: 10.1007/s40263-021-00825-w. Epub 2021 May 18. CNS Drugs. 2021. PMID: 34003459 Free PMC article. Review.
This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the …
This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investig …
Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology.
Zhou QQ, Guo J, Wang Z, Li J, Chen M, Xu Q, Zhu L, Xu Q, Wang Q, Pan H, Pan J, Zhu Y, Song M, Liu X, Wang J, Zhang Z, Zhang L, Wang Y, Cai H, Chen X, Lu G. Zhou QQ, et al. J Adv Res. 2023 Dec 10:S2090-1232(23)00377-6. doi: 10.1016/j.jare.2023.12.002. Online ahead of print. J Adv Res. 2023. PMID: 38072311 Free article.
OBJECTIVE: To overcome the PD-L1 heterogeneity and enable rapid, accurate, and label-free imaging of PD-L1 expression level in GBM IME at the tissue level. ...
OBJECTIVE: To overcome the PD-L1 heterogeneity and enable rapid, accurate, and label-free imaging of PD-L1 expression level in GBM IM …
DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
Zhu G, Liu Y, Yang X, Kim YH, Zhang H, Jia R, Liao HS, Jin A, Lin J, Aronova M, Leapman R, Nie Z, Niu G, Chen X. Zhu G, et al. Nanoscale. 2016 Mar 28;8(12):6684-92. doi: 10.1039/c5nr08821f. Nanoscale. 2016. PMID: 26947116 Free PMC article.
Mg2PPi renders hNVs resistant to nuclease degradation and thermal denaturation, both of which are demanding characteristics for effective vaccination and the storage and transportation of vaccines. Fluorophore-labeled hNVs were tracked to be efficiently internalized into t …
Mg2PPi renders hNVs resistant to nuclease degradation and thermal denaturation, both of which are demanding characteristics for effective va …
Plasma derived extracellular vesicle biomarkers of microglia activation in an experimental stroke model.
Roseborough AD, Myers SJ, Khazaee R, Zhu Y, Zhao L, Iorio E, Elahi FM, Pasternak SH, Whitehead SN. Roseborough AD, et al. J Neuroinflammation. 2023 Jan 31;20(1):20. doi: 10.1186/s12974-023-02708-x. J Neuroinflammation. 2023. PMID: 36721258 Free PMC article.
To model ischemia, plasma was collected from 3-month wildtype Fischer344 rats prior to, 7 and 28 days after endothelin-1 or saline injection into the dorsal right striatum. Fluorescently labelled MEVs were directly measured in the plasma using nanoflow cytometry (Apogee A6 …
To model ischemia, plasma was collected from 3-month wildtype Fischer344 rats prior to, 7 and 28 days after endothelin-1 or saline injection …
43 results